Dec 10 Love0 A Multi-center, Open-label Study to Evaluatethe Safety and Efficacy of a Sequential TreatmentRegimen of Clobetasol Propionate 0.05% SprayFollowed by Calcitriol 3 mg/g Ointment in theManagement of Plaque Psoriasis By No Comments Read More
Dec 10 Love0 Complete Clearance Is Sustained for at Least 12 Months After Treatment of Actinic Keratoses of the Face or Balding Scalp Via Daily Dosing With Imiquimod 3.75% or 2.5% Cream By No Comments INTRODUCTION Imiquimod 3.75% cream (Zyclaraâ„¢, Graceway Pharmaceuticals, LLC, Bristol, TN) is a new formulation of imiquimod recently approved by the U.S. Food and Drug Administration (FDA) to treat actinic keratoses…Read More
Dec 10 Love0 Effects of a Novel Formulation ofFluocinonide 0.1% Cream on Skin BarrierFunction in Atopic Dermatitis By No Comments Read More
Dec 10 Love0 The Erbium Micropeel: A Prospective, Randomized Trial of the Effects of Two Fluence Settings on Facial Photoaging By No Comments Read More
Dec 10 Love0 Part I: Program Spotlight The Harvard Combined Dermatology Residency Training Program By No Comments Read More
Dec 10 Love0 Disease and Treatment Burden of Psoriasis:Examining the Impact of Biologics By No Comments Read More
Dec 10 Love0 Part II: High-yield Dermatologic SignsThe Harvard Combined Program in Dermatology By No Comments Read More
Dec 10 Love0 Dermatologic Rituximab Dosing: Treatment of Refractory Pemphigus Vulgaris in an Adolescent Male By No Comments Read More
Dec 10 Love0 Part III: A. Cutaneous Hypersensitivity During Selective Serotonin Reuptake Inhibitor Therapy Resulting in Acquired Cutis Laxa. B. Levamisole-Induced Retiform Purpura By No Comments Read More